<DOC>
	<DOC>NCT02320474</DOC>
	<brief_summary>This is a one-year pilot, interventional, prospective, single arm, non-randomized, multicentric (3 centers) controlled study that aims to evaluate the response of type 3 choroidal neovascularization to treatment by Aflibercept following a classic protocol.</brief_summary>
	<brief_title>Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)</brief_title>
	<detailed_description />
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<criteria>Males or females aged more than 50 years Patients with type 3 choroidal neovascularization assessed on FA, ICG and OCT Exudation on SDOCT scans defined by intraretinal cysts or subretinal fluid. Best Corrected Visual Acuity at inclusion between 24 and 78 letters (ETDRS) Media clarity, pupillary dilation and patient cooperation sufficient to allow fundus photographs of adequate quality Any contraindications as reported in the labelling of Aflibercept (Eylea®): Ocular or periocular infection, Active intraocular inflammation or Hypersensitivity. Any previous history of intravitreal injections in the study eye for exudative AMD Any secondary chorioretinal anastomosis due to retinal scar or fibrosis Any history of vitrectomy Media opacities preventing accurate imaging of the retina (cataract) Any other retinal disorder possibly associated with type 3 CNV (epiretinal membrane, macular hole) Confirmed intraocular pressure ≥25 mmHg or nonstable glaucoma.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>